News | FFR Technologies | August 29, 2018

European Society of Cardiology Incorporates iFR Technology Into Updated Revascularization Guidelines

iFR-guided strategy now deemed beneficial in the assessment of the functional significance of intermediate coronary stenosis

European Society of Cardiology Incorporates iFR Technology Into Updated Revascularization Guidelines

August 29, 2018 — Philips announced that the European Society of Cardiology (ESC) has incorporated instantaneous wave-free ratio (iFR) into its updated revascularization guidelines. The new guidelines have provided the highest recommendation (class I A) for iFR alongside fractional flow reserve (FFR) for the objective assessment of the hemodynamic relevance of coronary lesions. In 2017, the DEFINE-FLAIR and iFR Swedeheart studies, the largest randomized coronary physiology outcome studies published to date, showcased iFR as a non-inferior method to FFR during risk stratification in coronary stenosis. iFR is a pressure-derived index unique to Philips, allowing a simplified hyperemia-free physiological assessment of coronary blockages to identify the appropriate therapy for each patient.

Ischemic heart disease (IHD) causes the highest rate of disability and death compared to any other illness in the world and also incurs the greatest economic costs. Of the approximately 17.7 million people who died from cardiovascular diseases globally in 2015, a total of 7.4 million were a result of coronary heart disease [1]. Philips began offering iFR technology as an alternative to FFR in 2013 in Europe and 2014 in the U.S. The technology offers a procedure that provides functional measurement while reducing patient discomfort by 90 percent, reducing costs by approximately 10 percent per patient over a one-year average and reducing time spent in the cath lab by 10 percent, according to Philips.

Click here to read the full updated ESC revascularization guidelines.

For more information:



[1] Cardiovascular diseases (CVDs). (n.d.). Retrieved from

Related iFR Content

Updated SCAI Expert Consensus Says Either FFR, iFR Can Be Used

Easier to Use iFR Equal to Outcomes of FFR in Coronary Lesion Evaluation

VIDEO: iFR Found More Cost Effective Over Standard FFR

VIDEO: iFR Equal to FFR Outcomes in Coronary Lesion Evaluation

Related Content

Sedentary Lifestyle Cancels Out Heart Benefits of Normal Weight
News | Cardiac Diagnostics | January 09, 2019
January 9, 2019 — Researchers at the University of Florida have found that low levels of physical activity can put he
Livongo Launches Applied Health Signals Product Category
News | Cardiac Diagnostics | November 30, 2018
Healthcare technology company Livongo recently announced the launch of its Applied Health Signals product category,...
HHS Releases Second Edition of Physical Activity Guidelines for Americans. #AHA2018 #AHA18
News | Cardiac Diagnostics | November 14, 2018
The U.S. Department of Health and Human Services (HHS) released the second edition of the Physical Activity Guidelines...
ACC and AHA Release Updated Cholesterol Guidelines for 2018. #AHA18 #AHA2018
Feature | Cardiac Diagnostics | November 13, 2018
November 13, 2018 — New cholesterol guidelines from the American Heart Association (AHA) and the American College of
AMI READMITS Score Predicts Heart Attack Patients at High Readmission Risk
News | Cardiac Diagnostics | October 09, 2018
Tracking just seven factors of heart attack patients when they are first admitted to the hospital can help flag those...
Siemens Healthineers Showcases New In Vivo and In Vitro Cardiovascular Solutions at TCT 2018
News | Cardiac Diagnostics | September 21, 2018
At the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference, Sept. 21-25 in San Diego, Siemens Healthineers...
Weight Loss Drug Does Not Increase Cardiovascular Events
News | Cardiac Diagnostics | August 31, 2018
A weight loss drug does not increase cardiovascular events, according to late breaking results from the CAMELLIA-TIMI...
Acarix Presents CADScor System at ESC 2018
News | Cardiac Diagnostics | August 27, 2018
Acarix AB’s ultra-sensitive acoustic CADScor System for coronary artery disease risk assessment will be on display at...
NIH Ending Funding for Moderate Alcohol and Cardiovascular Health Trial
News | Cardiac Diagnostics | August 24, 2018
The National Institutes of Health announced in June it plans to end funding to the Moderate Alcohol and Cardiovascular...
Study Shows Multiple Benefits of Patient-to-Patient Connectivity in Familial Chylomicronemia Syndrome
News | Cardiac Diagnostics | August 07, 2018
Akcea Therapeutics Inc., an affiliate of Ionis Pharmaceuticals Inc., announced the publication of results from the...
Overlay Init